Frequently Asked Questions
Answers to the questions we hear most often about GLP-1 medications, choosing a telehealth provider, insurance coverage, and how to use WeightLossRankings.org. Can't find what you're looking for? Email hello@weightlossrankings.org.
About Weight Loss Rankings
GLP-1 Medications
Choosing a Provider
Insurance & Cost
Using Our Site
Sources
The clinical, regulatory, and insurance answers above draw from the primary sources below. For the complete registry of every citation used across the site, see our master source list.
Sources & methodology — as of May 2026
- 1.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 2.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 3.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 7.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 9.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 10.CMS — Medicare Part D Prescription Drug Coverage Program— Centers for Medicare & Medicaid Services.
- 11.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 12.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
Still have questions?
We respond to most messages within one business day.
Email hello@weightlossrankings.orgOr visit our contact page.